Ullrich Greta, Bäuerle Alexander, Jahre Lisa Maria, Paldán Katrin, Rosemeyer Jana, Kalaitzidis Chiara, Rammos Christos, Teufel Martin, Rassaf Tienush, Lortz Julia
Department of Cardiology and Vascular Medicine, West-German Heart and Vascular Center Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.
Clinic for Psychosomatic Medicine and Psychotherapy, LVR-University Hospital Essen, Virchowstr. 175, 45147, Essen, Germany.
NPJ Digit Med. 2025 Jan 22;8(1):47. doi: 10.1038/s41746-024-01423-y.
This randomized, controlled trial evaluated the impact of plaque visualization combined with daily tasks on cardiovascular risk profile and included 240 participants with coronary arterial disease. The intervention group received the PreventiPlaque app during the 12-month study period in addition to standard care. The app contained daily tasks that promoted lifestyle modifications and adherence to prescribed medication. It included ultrasound images of participants´ individual carotid plaque, which were updated regularly. The impact of plaque visualization and personalized app usage was evaluated, using a change in the SCORE2 as a primary endpoint. In the intervention group, the SCORE2 was significantly lower after the study period (t(120) = 6.43, p < 0.001, d = 0.58). This demonstrates the efficacy of the PreventiPlaque app in supporting lifestyle modifications and medication adherence. These findings suggest that personalized mHealth interventions in combination with visual risk communication are valuable tools in secondary prevention. Trial Registration: The study was registered at ClinicalTrials.gov under the identifier NCT05096637 on 27 October 2021 and was approved by the local ethics committee of the University of Duisburg-Essen (20-9157-BO).
这项随机对照试验评估了斑块可视化结合日常任务对心血管风险状况的影响,纳入了240名冠状动脉疾病患者。在为期12个月的研究期间,干预组除接受标准护理外,还使用了PreventiPlaque应用程序。该应用程序包含促进生活方式改变和遵医嘱服药的日常任务。它包括参与者个体颈动脉斑块的超声图像,并定期更新。以SCORE2的变化作为主要终点,评估斑块可视化和个性化应用程序使用的影响。在干预组中,研究期结束后SCORE2显著降低(t(120) = 6.43,p < 0.001,d = 0.58)。这证明了PreventiPlaque应用程序在支持生活方式改变和药物依从性方面的有效性。这些发现表明,个性化移动健康干预与视觉风险沟通相结合是二级预防中的宝贵工具。试验注册:该研究于2021年10月27日在ClinicalTrials.gov上注册,标识符为NCT05096637,并获得了杜伊斯堡-埃森大学当地伦理委员会的批准(20-9157-BO)。